Healthcare [ 7/13 ] | Diagnostics & Research [ 58/163 ]
NYSE | Common Stock
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide.
The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab.
The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
The Diagnostics and Genomics segment focuses on genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses.
The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and offers services portfolio, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services.
The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce.
Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 29, 24 | 1.22 Decreased by -3.94% | 1.19 Increased by +2.52% |
| Feb 27, 24 | 1.29 Decreased by -5.84% | 1.22 Increased by +5.74% |
| Nov 20, 23 | 1.38 Decreased by -9.80% | 1.34 Increased by +2.99% |
| Aug 15, 23 | 1.43 Increased by +6.72% | 1.36 Increased by +5.15% |
| May 23, 23 | 1.27 Increased by +12.39% | 1.26 Increased by +0.79% |
| Feb 28, 23 | 1.37 Increased by +13.22% | 1.30 Increased by +5.38% |
| Nov 21, 22 | 1.53 Increased by +26.45% | 1.39 Increased by +10.07% |
| Aug 16, 22 | 1.34 Increased by +21.82% | 1.20 Increased by +11.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Apr 30, 24 | 1.57 B Decreased by -8.39% | 308.00 M Increased by +1.99% | Increased by +19.58% Increased by +11.32% |
| Jan 31, 24 | 1.66 B Decreased by -5.58% | 348.00 M Decreased by -1.14% | Increased by +20.99% Increased by +4.71% |
| Oct 31, 23 | 1.69 B Decreased by -8.71% | 475.00 M Increased by +29.08% | Increased by +28.14% Increased by +41.39% |
| Jul 31, 23 | 1.67 B Decreased by -2.68% | 111.00 M Decreased by -66.26% | Increased by +6.64% Decreased by -65.33% |
| Apr 30, 23 | 1.72 B Increased by +6.85% | 302.00 M Increased by +10.22% | Increased by +17.59% Increased by +3.16% |
| Jan 31, 23 | 1.76 B Increased by +4.90% | 352.00 M Increased by +24.38% | Increased by +20.05% Increased by +18.57% |
| Oct 31, 22 | 1.85 B Increased by +11.39% | 368.00 M Decreased by -16.74% | Increased by +19.90% Decreased by -25.25% |
| Jul 31, 22 | 1.72 B Increased by +8.32% | 329.00 M Increased by +24.62% | Increased by +19.15% Increased by +15.05% |